Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 51

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 51
---
 to offset the associated acquisition and main...  

In addition, if we undertake
acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible
assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities
and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development
of our business.

If we fail to comply with the U. S. Foreign
Corrupt Practices Act (“ FCPA”), or other anti-bribery laws, including the Bribery Act 2010 of the United Kingdom (UK
Bribery Act”), our reputation may be harmed and we could be subject to penalties and significant expenses that have a material adverse
effect on our business, financial condition and results of operations.

We are subject to the FCPA.
The FCPA and UK Bribery Act generally prohibits us from making improper payments to non-U. S. officials for the purpose of obtaining or
retaining business or other benefits. We are also subject to the anti-bribery laws of other jurisdictions, particularly the PRC. As our
business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls
to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we,
due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation
could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material
adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.

Our business and results of operations may
be negatively impacted by the UK’s withdrawal from the EU.

On June 23, 2016, the UK held
a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020.
There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However,
the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and
has been formally applicable since May